Combination of lymphoproliferative diseases and pregnancy

Cover Page

Cite item

Full Text

Abstract

The article presents an analysis of the current state of the problem of the combination of lymphoproliferative diseases associated with pregnancy. Analysis of literature sources has shown that despite the seemingly obvious unfavorable relationship between pregnancy and lymphoproliferative diseases, most studies demonstrate a favorable prognosis regarding the prognosis and outcome of this oncological pathology in combination with pregnancy. The Research Institute of Oncology of the Tomsk SRI has sufficient experience in the treatment of this pathology, including on the background of pregnancy. We have presented two clinical cases in which successful treatment of lymphoproliferative processes in pregnant women has been demonstrated.

About the authors

A. L. Chernyshova

Research Institute of Oncology, Tomsk National Research Medical Center, Russian Academy of Sciences

Author for correspondence.
Email: alacher@list.ru
ORCID iD: 0000-0002-8194-2811

Alena L. Chernyshova 

5 Kooperativnyy Pereulok, Tomsk 634009

Russian Federation

A. A. Chernyakov

Research Institute of Oncology, Tomsk National Research Medical Center, Russian Academy of Sciences

ORCID iD: 0000-0003-0829-0340

5 Kooperativnyy Pereulok, Tomsk 634009

Russian Federation

N. O. Popova

Research Institute of Oncology, Tomsk National Research Medical Center, Russian Academy of Sciences

ORCID iD: 0000-0001-5294-778X

5 Kooperativnyy Pereulok, Tomsk 634009

Russian Federation

T. L. Kravchuk

Research Institute of Oncology, Tomsk National Research Medical Center, Russian Academy of Sciences

ORCID iD: 0000-0002-2048-3404

5 Kooperativnyy Pereulok, Tomsk 634009

Russian Federation

Yu. M. Trushchuk

Research Institute of Oncology, Tomsk National Research Medical Center, Russian Academy of Sciences

5 Kooperativnyy Pereulok, Tomsk 634009

Russian Federation

O. S. Dil’

Research Institute of Oncology, Tomsk National Research Medical Center, Russian Academy of Sciences

ORCID iD: 0000-0001-6562-7574

5 Kooperativnyy Pereulok, Tomsk 634009

Russian Federation

S. E. Krasil’nikov

E.N. Meshalkin National Medical Research Center, Ministry of Health of Russia

ORCID iD: 0000-0003-0687-0894

15 Rechkunovskaya St., Novosibirsk 630055

Russian Federation

V. A. Antipov

E.N. Meshalkin National Medical Research Center, Ministry of Health of Russia

ORCID iD: 0000-0003-3522-4920

15 Rechkunovskaya St., Novosibirsk 630055

Russian Federation

A. O. Shumeykina

E.N. Meshalkin National Medical Research Center, Ministry of Health of Russia

15 Rechkunovskaya St., Novosibirsk 630055

Russian Federation

References

  1. State of oncological care in Russia in 2021. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2022. 239 p. (In Russ.).
  2. Zhang J., Shynlova O., Sabra S. et al. Immunophenotyping and activation status of maternal peripheral blood leukocytes during pregnancy and labour, both term and preterm. J Cell Mol Med 2017;21(10):2386–402. doi: 10.1111/jcmm.13160
  3. Abu-Raya B., Michalski C., Sadarangani M., Lavoie P.M. Maternal immunological adaptation during normal pregnancy. Front Immunol 2020;11:575197. doi: 10.3389/fimmu.2020.575197
  4. Mehta A.K., Kadel S., Townsend M.G. et al. Macrophage biology and mechanisms of immune suppression in breast cancer. Front Immunol 2021;12:643771. doi: 10.3389/fimmu.2021.643771
  5. Jungles K.M., Holcomb E.A., Pearson A..N et al. Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer. Front Oncol 2022;12:1022542. doi: 10.3389/fonc.2022.1022542
  6. Ruocco M.G., Chaouat G., Florez L. et al. Regulatory T-cells in pregnancy: historical perspective, state of the art, and burning questions. Front Immunol 2014;5:389. doi: 10.3389/fimmu.2014.00389
  7. Kushekhar K., van den Berg A., Nolte I. et al. Genetic associations in classical hodgkin lymphoma: a systematic review and insights into susceptibility mechanisms. Cancer Epidemiol Biomark Prev 2014;23(12):2737–47. doi: 10.1158/1055-9965.EPI-14-0683
  8. Gaudio F., Perrone T., Mestice A. et al. Peripheral blood CD4/ CD19 cell ratio is an independent prognostic factor in classical Hodgkin lymphoma. Leuk Lymphoma 2014;55(7):1596–601. doi: 10.3109/10428194.2013.854889
  9. Gaudio F., Nardelli C., Masciandaro P. et al. Pregnancy rate and outcome of pregnancies in long-term survivors of Hodgkin’s lymphoma. Ann Hematol 2019;98(8):1947–52. doi: 10.1007/s00277-019-03684-0
  10. Maggen C., Dierickx D., Lugtenburg P. et al. International Network on Cancer, Infertility and Pregnancy. Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study. Lancet Haematol 2019;6(11):e551–61. doi: 10.1016/S2352-3026(19)30195-4
  11. Chernyshova A.L., Kolomiets L.A., Chernyakov A.A. et al. Features of the course of melanoma during pregnancy. Voprosy onkologii = Problems in Oncology 2023;69(2):322–7. (In Russ.). doi: 10.37469/0507-3758-2023-69-2-322-327
  12. Dell’Aquila K., Hodges H., Moshiri M. et al. Imaging evaluation of lymphoma in pregnancy with review of clinical assessment and treatment options. Abdom Radiol (NY) 2023;48(5):1663–78. doi: 10.1007/s00261-022-03779-9
  13. Moshe Y., Bentur O.S., Lishner M., Avivi I. The management of Hodgkin lymphomas in pregnancies. Eur J Haematol 2017;99(5):385–91. doi: 10.1111/ejh.12956
  14. Shah M.R., Brandt J.S., David K.A., Evens A.M. Lymphoma occurring during pregnancy: current diagnostic and therapeutic approaches. Curr Oncol Rep 2020;22(11):113. doi: 10.1007/s11912-020-00972-1
  15. Aviles A., Nambo M.J., Neri N. Lymphoma and pregnancy. Jpn J Clin Oncol 2017;47(5):467–8. doi: 10.1093/jjco/hyx004
  16. Di Ciaccio P.R., Mills G., Shipton M.J. et al. The clinical features, management and outcomes of lymphoma in pregnancy: a multicentre study by the Australasian Lymphoma Alliance. Br J Haematol 2023;201(5):887–96. doi: 10.1111/bjh.18727
  17. El-Messidi A., Patenaude V., Abenhaim H.A. Incidence and outcomes of women with non-Hodgkin’s lymphoma in pregnancy: a population-based study on 7.9 million births. J Obstet Gynaecol Res 2015;41(4):582–9. doi: 10.1111/jog.12597
  18. Maggen C., Dierickx D., Cardonick E. et al. International Network on Cancer Infertility Pregnancy (INCIP). Maternal and neonatal outcomes in 80 patients diagnosed with non-Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy. Br J Haematol 2021;193(1):52–62. doi: 10.1111/bjh.17103
  19. Flint T.R., Jones J.O., Ferrer M. et al. A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy. Sem Oncol 2018;45(3):170–5. doi: 10.1053/j.seminoncol.2018.03.005
  20. Luttwak E., Gurevich-Shapiro A., Azem F. et al. Novel agents for the treatment of lymphomas during pregnancy: a comprehensive literature review. Blood Rev 2021;49:100831. doi: 10.1016/j.blre.2021.100831
  21. On S., Chang A. Treatment of lymphoma with rituximab and chemotherapy during pregnancy. Leuk Lymphoma 2022;63(12):2897–904. doi: 10.1080/10428194.2022.2100368

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36928 от  21.07.2009.